U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C24H24FN3O2.ClH
Molecular Weight 441.926
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ADOPRAZINE HYDROCHLORIDE

SMILES

Cl.FC1=CC=C(C=C1)C2=CN=CC(CN3CCN(CC3)C4=CC=CC5=C4OCCO5)=C2

InChI

InChIKey=PAPGPUNOWOEIPA-UHFFFAOYSA-N
InChI=1S/C24H24FN3O2.ClH/c25-21-6-4-19(5-7-21)20-14-18(15-26-16-20)17-27-8-10-28(11-9-27)22-2-1-3-23-24(22)30-13-12-29-23;/h1-7,14-16H,8-13,17H2;1H

HIDE SMILES / InChI
Molecular Formula C24H24FN3O2
Molecular Weight 405.4647
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE
Molecular Formula ClH
Molecular Weight 36.461
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: description was created based on several sources, including http://www.solvay.com/en/binaries/20080930_Pharma-135290.pdf

Adoprazine (SVL-313) is a full 5-HT1A receptor agonist and full D2/3 receptor antagonist possessing characteristics of an atypical antipsychotic, representing a potential novel treatment for schizophrenia and bipolar disorder. This drug together with some others, e.g. Mazapertine succinate, PF-217830 was discontinued from clinical trials due to either non-optimal pharmacokinetic properties or insufficient therapeutical efficacy.

Originator

Approval Year

Unknown
139594
Targets

Targets

Primary TargetPharmacologyConditionPotency
Agonist
2678
 9.0 null [pEC50]
Antagonist
2778
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Phase I
428
Unknown

Approved Use

Unknown
Primary
Phase I
428
Unknown

Approved Use

Unknown
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG
inhibitor
1587
inhibitor
1767
inhibitor
1852

OverviewOther

Other InhibitorOther SubstrateOther Inducer
P-gp
1537
Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
CYP2C9
1819
 yes [IC50 10.684 uM]
CYP3A4
1925
 yes [IC50 4.7724 uM]
CYP2D6
1891
 yes [IC50 9.5221 uM]
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
P-gp
1537
 no
Sourcing

Sourcing

Vendor/AggregatorIDURL
1PlusChem LLC
1P00BFIN
https://www.1pchem.com/search?query=1P00BFIN
AK Scientific
3422AH
https://aksci.com/item_detail.php?cat=3422AH
BLD Pharm
BD630557
http://www.bldpharm.com/search/Search.html?keyword=BD630557
BOC Sciences
222551-17-9
http://www.bocsci.com/description.asp?cas=222551-17-9
Chem Scene
CS-0673
http://www.chemscene.com/goproductList/searchProductList?productObj=CS-0673
MedChem Express
HY-14782
https://www.medchemexpress.com/search.html?q=HY-14782&ft=&fa=&fp=
MolPort
MolPort-039-139-539
https://www.molport.com/shop/molecule-link/MolPort-039-139-539
MuseChem
I001228
https://www.musechem.com/product/I001228.html
eMolecules
44811502
https://orderbb.emolecules.com/search/#?query=44811502
mcule
MCULE-3822913051
https://mcule.com/MCULE-3822913051/
PubMed

PubMed

TitleDatePubMed
SAR study of 1-aryl-4-(phenylarylmethyl)piperazines as ligands for both dopamine D2 and serotonin 5-HT1A receptors showing varying degrees of (Ant)agonism. Selection of a potential atypical antipsychotic.
2006 Sep
Differences among conventional, atypical and novel putative D(2)/5-HT(1A) antipsychotics on catalepsy-associated behaviour in cynomolgus monkeys.
2009 Nov 5
Patents

Patents

20070049576
12

Sample Use Guides

In Vivo Use Guide
ablets taken once daily for 14 days
Route of Administration: Oral
In Vitro Use Guide
Curator's Comment: SLV313 (ADOPRAZINE) possessed high affinity at human recombinant D(2), D(3), D(4), 5-HT(2B), and 5-HT(1A) receptors, moderate affinity at 5-HT(7) and weak affinity at 5-HT(2A) receptors, with little-no affinity at 5-HT(4), 5-HT(6), alpha(1), and alpha(2) (rat), H(1) (guinea pig), M(1), M(4), 5-HT(3) receptors, and the 5-HT transporter. SLV313 had full agonist activity at cloned h5-HT(1A) receptors (pEC(50)=9.0) and full antagonist activity at hD(2) (pA(2)=9.3) and hD(3) (pA(2)=8.9) receptors.
Unknown
Substance Class Chemical
Created
by admin
on Sat Dec 16 08:12:32 GMT 2023
Edited
by admin
on Sat Dec 16 08:12:32 GMT 2023
Record UNII
R8E4GUG6DQ
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
ADOPRAZINE HYDROCHLORIDE
Common Name English
ADOPRAZINE MONOHYDROCHLORIDE
Common Name English
SLV-313
Code English
1-(2,3-DIHYDRO-BENZO(1,4)DIOXIN-5-YL)-4- (5-(4-FLUORO-PHENYL)-PYRIDIN-3-YLMETHYL)-PIPERAZINE MONOHYDROCHLORIDE
Systematic Name English
PIPERAZINE, 1-(2,3-DIHYDRO-1,4-BENZODIOXIN-5-YL)-4-((5-(4-FLUOROPHENYL)-3-PYRIDINYL)METHYL)-, HYDROCHLORIDE (1:1)
Systematic Name English
Code System Code Type Description
PUBCHEM
42631781
Created by admin on Sat Dec 16 08:12:32 GMT 2023 , Edited by admin on Sat Dec 16 08:12:32 GMT 2023
PRIMARY
CAS
222551-05-5
Created by admin on Sat Dec 16 08:12:32 GMT 2023 , Edited by admin on Sat Dec 16 08:12:32 GMT 2023
PRIMARY
FDA UNII
R8E4GUG6DQ
Created by admin on Sat Dec 16 08:12:32 GMT 2023 , Edited by admin on Sat Dec 16 08:12:32 GMT 2023
PRIMARY
Related Record Type Details
Structure of ADOPRAZINE
PARENT -> SALT/SOLVATE
Related Record Type Details
Structure of ADOPRAZINE
ACTIVE MOIETY
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966